Skip to content
FindTrial
Search trials
Search trials by condition, treatment, sponsor...
Sign In
RXDX-105
DRUG
3 trials
Sponsors
Hoffmann-La Roche
, Memorial Sloan Kettering Cancer Center
Conditions
BRAF Gene Mutation
Cancers With RET Alterations
Non Small Cell Lung Cancer
Ovarian Cancer
RET Gene Mutation
Solid Tumors
Phase 1
Study of RXDX-105, Potent RET Inhibitor in Patients With Advanced Lung Cancer and Other Solid Tumors
Completed
NCT01877811
Hoffmann-La Roche
Solid Tumors
Start: 2013-06-30
End: 2019-02-28
Updated: 2019-04-25
Continued Access to RXDX-105
Completed
NCT03784378
Memorial Sloan Kettering Cancer Center
BRAF Gene Mutation, Non Small Cell Lung Cancer, Ovarian Cancer +1
Start: 2018-12-14
End: 2020-09-30
Updated: 2025-05-15
Unknown Phase
Expanded Access to RXDX-105 for Cancers With RET Alterations
NCT03052569
Hoffmann-La Roche
Cancers With RET Alterations
Updated: 2019-04-26
Related Papers
RET fusions in a small subset of advanced colorectal cancers at risk of being neglected.
2018-06-01
84 citations
A phase 1 dose escalation study of RXDX-105, an oral RET and BRAF inhibitor, in patients with advanced solid tumors.
Journal of Clinical Oncology
2016-05-20
6 citations